1098-1128/asset/MED_left.gif?v=1&s=ffeae5c9082b4a721dd696f764dc3655ebfa61c5)
Review Article
Tenofovir: Quo Vadis Anno 2012 (Where Is It Going in the Year 2012)?
Article first published online: 11 MAY 2012
DOI: 10.1002/med.21267
© 2012 Wiley Periodicals, Inc.
Issue
Medicinal Research Reviews
Special Issue: Special Issue Dedicated to Professor Lester A. Mitscher
Volume 32, Issue 4, pages 765–785, July 2012
Additional Information
How to Cite
De Clercq, E. (2012), Tenofovir: Quo Vadis Anno 2012 (Where Is It Going in the Year 2012)?. Med. Res. Rev., 32: 765–785. doi: 10.1002/med.21267
Publication History
- Issue published online: 8 JUL 2012
- Article first published online: 11 MAY 2012
- Abstract
- Article
- References
- Cited By
Keywords:
- acyclic nucleoside phosphonates (ANPs);
- tenofovir;
- tenofovir disoproxil fumarate (TDF);
- Viread®;
- Truvada®;
- Atripla®;
- Complera®;
- QUAD
Abstract
Twenty years after its original discovery, tenofovir has acquired a crucial position in the fight against human immunodeficiency virus (HIV). First, tenofovir disoproxil fumarate (TDF) is not only efficacious against, and has been licensed for the treatment of HIV (AIDS), but also HBV (hepatitis B). Second, for the treatment of HIV infections, TDF can be used in combination with other anti-HIV drugs, such as emtricitabine (combination termed Truvada®) and Truvada can be further combined with efavirenz, rilpivirine, elvitegravir, atazanavir, or darunavir, as a single once-daily oral pill. Third, Truvada can be used prophylactically to prevent transmission of HIV infection. And fourth, to prevent sexual HIV transmission, tenofovir could also be used topically (i.e., as a vaginal gel). © 2012 Wiley Periodicals, Inc. Med Res Rev., 32, No. 4, 765-785, 2012